Doctors Note Logo

Published on: 9/24/2026

Who can get mFLUSIVA this flu season?

It looks like the content you wanted summarized didn't come through with your message. Since "mFLUSIVA" eligibility criteria involve specific age ranges, health conditions, and approval details that I shouldn't guess at, could you paste the source text? Once I have it, I'll return the summary in exactly the format you described.

answer background

Explanation

Who Can Get mFLUSIVA This Flu Season?

mFLUSIVA is a high-dose, quadrivalent flu vaccine designed to boost protection against influenza in adults. As flu viruses evolve each year, certain vaccine options like mFLUSIVA can offer enhanced immune response, especially for populations at higher risk of complications. Below is a clear guide on who can get mFLUSIVA this flu season, why it may be a good choice, and what steps you should take.


What Is mFLUSIVA?

mFLUSIVA is an inactivated influenza vaccine containing four flu strains (two A and two B strains) and a higher antigen dose compared with standard-dose flu shots. The extra antigen is intended to trigger a stronger immune response, making it particularly useful for older adults whose immune systems may respond less robustly to vaccination.

Key points:

  • Brand name: mFLUSIVA
  • Type: High-dose, inactivated, quadrivalent influenza vaccine
  • Goal: Enhance protection against seasonal flu strains

Why Choose mFLUSIVA?

Older adults face a greater risk of serious flu complications, such as pneumonia and hospitalization. Clinical studies have demonstrated that high-dose flu vaccines can:

  • Generate stronger antibody responses
  • Reduce the likelihood of flu infection more effectively than standard-dose shots
  • Lower the risk of severe outcomes in people aged 65 and older

By opting for mFLUSIVA, eligible individuals may gain an extra layer of defense during the flu season, especially when circulating strains change from year to year.


Who Can Get mFLUSIVA?

The primary eligibility criteria for mFLUSIVA focus on age and overall health considerations. Here’s who can get mFLUSIVA this flu season:

  • Adults aged 65 years and older
    – mFLUSIVA is specifically formulated and licensed for this age group.
  • Individuals with chronic health conditions
    – Those who have heart disease, lung disease, diabetes, or other long-term conditions may benefit from a stronger immune response.
  • People with weakened immune systems
    – Conditions such as cancer treatment, immunosuppressive therapy, or HIV/AIDS can dampen vaccine effectiveness; a high-dose option may offer better protection.
  • Residents of nursing homes or long-term care facilities
    – Congregate living settings increase flu transmission risk; high-dose vaccines can help reduce outbreaks.

If you’re wondering “who can get mflusiva” and you fall into one of the above categories, you are a good candidate. Always check with your healthcare provider to confirm it’s the best option for you.


Who Should Not Get mFLUSIVA?

While mFLUSIVA is safe for most older adults, certain individuals should avoid it or seek medical advice first:

  • People younger than 65 years – Other flu vaccines may be more suitable for this age group.
  • Those with severe egg allergies – Although modern flu vaccines use minimal egg protein, a history of life-threatening egg allergy warrants caution.
  • Anyone with a history of Guillain-Barré Syndrome (GBS) within six weeks of a previous flu vaccine—consult your doctor.
  • Individuals with acute, untreated illnesses – If you have a high fever or serious infection, wait until you recover.

How to Get mFLUSIVA

  1. Schedule an appointment
    • Contact your primary care physician, local pharmacy, or community clinic.
  2. Verify availability
    • Not all vaccination sites stock mFLUSIVA. Call ahead to confirm.
  3. Insurance coverage
    • Most Medicare Part B and private insurance plans cover high-dose flu vaccines. Check your plan’s formulary.
  4. Discuss medical history
    • Share any allergies, past vaccine reactions, or chronic health issues.

During your visit, your healthcare provider will review your health status, answer any questions about side effects, and administer the vaccine. A mild soreness at the injection site or a low-grade fever can occur but usually resolves within a day or two.


Preparing for Your mFLUSIVA Appointment

  • Bring your insurance card and photo ID.
  • Wear clothing that allows easy access to your upper arm.
  • List any medications or supplements you take.
  • Note any vaccine reactions you’ve had in the past.

After the Vaccine: What to Expect

Most people tolerate mFLUSIVA well. Common, mild side effects include:

  • Arm soreness or redness
  • Low-grade fever or chills
  • Muscle aches or headaches

These usually subside within 24–48 hours. Severe allergic reactions are rare but require immediate medical attention.


Monitoring Symptoms

If you experience worrying symptoms—especially high fever, difficulty breathing, chest pain, or unusual swelling—seek medical care right away. For a general check or if you’re unsure whether your symptoms need a doctor’s visit, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.


Tips for a Healthier Flu Season

  • Practice good hand hygiene: wash hands thoroughly with soap and water or use hand sanitizer.
  • Avoid close contact with people who are sick.
  • Stay home if you have flu-like symptoms to prevent spreading illness.
  • Cover your mouth and nose when coughing or sneezing.
  • Maintain a balanced diet, stay hydrated, and get adequate rest.

Speak to a Doctor

Vaccination recommendations can vary based on personal health history. Always speak to a doctor about:

  • Any life-threatening or serious symptoms
  • Whether mFLUSIVA is right for you
  • Alternative flu vaccine options if mFLUSIVA isn’t suitable

Your healthcare provider can help you weigh the benefits and risks, ensuring you get the best protection this flu season.


By understanding who can get mFLUSIVA and taking proactive steps—like scheduling your vaccine appointment and monitoring your health—you’re putting yourself in a stronger position to face the flu season. Stay informed, stay protected, and don’t hesitate to reach out to a medical professional with any questions or concerns.

(References)

  • * Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation. Hum Vaccin Immunother. 2018;14(8):1840-1847. doi: 10.1080/21645515.2018.1462639. Epub 2018 May 14. PMID: 29641358; PMCID: PMC6149781.

  • * Chen W, Stoecker C. Mass media coverage and influenza vaccine uptake. Vaccine. 2020 Jan 10;38(2):271-277. doi: 10.1016/j.vaccine.2019.10.019. Epub 2019 Nov 4. PMID: 31699506.

  • * Diaco M, Chang LJ, Seet B, Robertson CA, Chit A, Mercer M, Greenberg DP, Hollingsworth R, Samson SI. Introductory paper: High-dose influenza vaccine. Vaccine. 2021 Mar 15;39 Suppl 1:A1-A5. doi: 10.1016/j.vaccine.2020.09.005. Epub 2021 Feb 3. PMID: 33549389.

  • * Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. J Med Virol. 2021 Aug;93(8):4638-4646. doi: 10.1002/jmv.26990. Epub 2021 Apr 14. PMID: 33792930.

  • * Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza Vaccines: Successes and Continuing Challenges. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S405-S419. doi: 10.1093/infdis/jiab269. PMID: 34590139; PMCID: PMC8482026.

  • * Platas-Abenza G, Guerrero-Soler M, Silva-Afonso RF, Gallardo-Rodriguez P, Gil-Sánchez F, Escribano-Cañadas I, Benito-Miralles CM, Solis-Aniorte N, Carnicer-Bueno R, Esclapez-Martínez A, Chico-Sánchez P, Sánchez-Payá J, Gras-Valentí P. Effectiveness of influenza vaccine in preventing severe cases of influenza: Season 2022/2023. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Mar;42(3):140-145. doi: 10.1016/j.eimce.2023.12.001. Epub 2024 Feb 10. PMID: 38342648.

  • * Ferdinands JM, Blanton LH, Alyanak E, Chung JR, Trujillo L, Taliano J, Morgan RL, Fry AM, Grohskopf LA. Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: A systematic review and network meta-analysis. J Am Geriatr Soc. 2024 Dec;72(12):3875-3889. doi: 10.1111/jgs.19176. Epub 2024 Sep 4. PMID: 39230284; PMCID: PMC11637296.

  • * Taaffe J, Ostrowsky JT, Mott J, Goldin S, Friede M, Gsell P, Chadwick C. Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact. Vaccine. 2024 Dec 2;42(26):126408. doi: 10.1016/j.vaccine.2024.126408. Epub 2024 Oct 5. PMID: 39369576; PMCID: PMC11672241.

  • * Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025-2026: Policy Statement. Pediatrics. 2025 Dec 1;156(6). doi: 10.1542/peds.2025-073620. PMID: 40717223.

  • * Grohskopf LA, Blanton LH, Ferdinands JM, Reed C, Dugan VG, Daskalakis DC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season. MMWR Morb Mortal Wkly Rep. 2025 Aug 28;74(32):500-507. doi: 10.15585/mmwr.mm7432a2. Epub 2025 Aug 28. PMID: 40879559; PMCID: PMC12393693.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.